Up next

Autoplay

The future of CTCL therapy

4 Views • 08/09/23
Share
Embed
administrator
administrator
Subscribers
0

Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, suggests how the therapeutic landscape of cutaneous T-cell lymphoma (CTCL) may evolve in the future, with the development of novel monoclonal antibodies, oncogenic peptides, and agents targeting overactivated signaling pathways in CTCL. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay